Primary entity: ATX-304Also known as: O-304 / O304Class: Investigational AMPK activator — not a peptideCluster: GLP-1 & metabolic
ATX-304 is an investigational oral small molecule developed as a pan-/network AMPK activator (with mitochondrial/energy-expenditure narratives), formerly coded O-304. Peer-reviewed work under the O-304 name and later sponsor materials under ATX-304 describe metabolic and cardiometabolic research contexts (including type 2 diabetes proof-of-concept and obesity/prediabetes translational studies). It is not a peptide, not FDA-approved, and is not available as a licensed medicine and is not an FDA-approved medicine. Published efficacy evidence cited here is preclinical.
If you landed here from “peptides for weight loss” or AMPK “exercise mimetic” forums, know that ATX-304 is included for cluster literacy, not because it is a peptide hormone analogue. It is a small molecule.
Not FDA-approved. Not an approved U.S. obesity or diabetes drug. Historical clinical work exists under O-304 (including a published Phase IIa-style T2D proof-of-concept on metformin) and later ATX-304 sponsor disclosures (Phase 1b obesity/prediabetes translational data; Phase 2 obesity/cardiometabolic plans described by Cambrian Bio). Pipeline phase labels, when they appear in company materials, are sponsor claims and are not treated as verified here. Gray-market “research” products claiming ATX-304 identity are not the investigational clinical supply.
Key takeaways
- Not a peptide — oral small-molecule AMPK activator (formerly O-304); mitochondrial energy-expenditure / uncoupling themes appear in research narratives.
- Discussed for metabolic / cardiometabolic contexts (T2D proof-of-concept history; obesity and MASLD-adjacent preclinical work) — studied ≠ approved.
- Not FDA-approved; do not treat vendor “research” powders/capsules as licensed therapy.
- Distinct from AICAR-class AMPK tools and from incretin peptide drugs (semaglutide, tirzepatide).
- No dosage chart on this site.
Questions this page answers
- What is ATX-304?
- Aliases / O-304 naming
- Classification — why it’s on a peptide site
- What it is NOT
- Mechanism (AMPK / mitochondria)
- Evidence ladder
- What has been studied
- Safety literacy
- Regulatory snapshot
- Why no dosages
- Related metabolic agents
- Who for / not for
Who is this profile for — and who is it not for?
For: readers comparing metabolic pharmacology classes who need accurate “is this a peptide?” and “is this approved?” literacy for an AMPK-pathway investigational candidate.
Not for: anyone seeking a buy link, an “exercise mimetic protocol,” gray-market dosing, or medical advice.
What is ATX-304?
ATX-304 (formerly O-304) is described in the literature and sponsor materials as a direct / pan-AMPK activator that increases AMPK activity by mechanisms including protection against dephosphorylation of the activating Thr172 site — rather than simply mimicking AMP at the γ subunit the way classic AMP-mimetics do. Research narratives also describe increased mitochondrial respiration / proton conductance (mild uncoupling framing) with claims that cellular ATP can be preserved at tested concentrations.
| Chemistry class | Oral small-molecule AMPK network activator (± mild mitochondrial uncoupler narratives) |
|---|---|
| Peptide? | No |
| Former code | O-304 / O304 |
| Route discussed in trials | Oral |
| Typical discussion contexts | Obesity, cardiometabolic disease, T2D/metabolic research |
| U.S. approval | Not approved (as of November 10, 2026) |
Also known as
- O-304 / O304 — earlier development and publication name (including human T2D proof-of-concept work).
- ATX-304 — current sponsor code used by Cambrian Bio / Amplifier Therapeutics framing.
- Folk/mis-tags: “ATX-304 peptide,” “O304 peptide,” “AMPK peptide” — chemistry errors.
Forum and AI answers sometimes file ATX-304 with research peptides because of weight-loss and “exercise mimetic” SERP adjacency. Correct the class first (small molecule), then discuss evidence maturity.
How is ATX-304 classified?
Investigational oral small molecule targeting the AMPK energy-sensing network, with additional mitochondrial/energy-expenditure narratives. On this site it sits in the glp1-metabolic cluster for educational comparison with peptide anti-obesity drugs — with an explicit not-a-peptide banner.
It is not a dietary supplement, not an FDA-approved drug, and not interchangeable with research-chemical vendor products.
What is ATX-304 not?
| ATX-304 is not… | Why that matters |
|---|---|
| A peptide / GLP-1 or GIP agonist | Different chemistry and targets |
| FDA-approved in the U.S. | No U.S. label |
| Synonymous with “oral Ozempic” | False analogy to incretin peptides |
| The same tool as AICAR | Different AMPK activation chemistry / development story |
| Something we dose or source | Refusal |
| Guaranteed identical to gray-market “ATX-304” | Product identity/purity unknown |
How is ATX-304 thought to work?
At a literacy level: activating AMPK is associated in research with shifts toward glucose and fatty-acid uptake, reduced lipogenesis pathways, and greater oxidative metabolism. Sponsor and preclinical narratives also emphasize raising energy expenditure via mitochondrial proton conductance while aiming to keep cellular energy charge intact — i.e., not simply crashing ATP to force AMPK on. This is not incretin-receptor agonism and not monoamine reuptake inhibition.
For advanced readers: isoform coverage (pan-AMPK / “network” framing), peripheral restriction claims, and uncoupling vs AMPK-primary causality remain active interpretation topics — prefer peer-reviewed methods papers over marketing slides.
What human vs animal vs label evidence exists?
| Evidence type | What exists (summary) | Maturity |
|---|---|---|
| Human — O-304 era | Published T2D proof-of-concept (TELLUS-style) on metformin | Human Early / exploratory — verify paper |
| Human — ATX-304 era | Sponsor Phase 1b obesity/prediabetes translational disclosures (e.g., ADA poster era) | Human Early — verify full peer-reviewed write-up |
| Preclinical | Obese-mouse metabolic, cardiac, MASLD/MASH-adjacent liver work | Animal |
| Approved U.S. label | None | None |
| Gray-market vendor claims | Not clinical evidence | None |
Avoid inventing exact % weight-loss, liver-fat, or energy-expenditure figures in evergreen copy without locked citations.
What has ATX-304 been studied for?
Contexts appearing in literature and sponsor materials include type 2 diabetes / glucose homeostasis (O-304 era), obesity and cardiometabolic development plans (ATX-304 era), and MASLD / liver metabolic switching in preclinical models. Studied ≠ approved. Exercise-endurance narratives in animals are research findings, not athletic recommendations.
What safety topics come up?
Public clinical disclosures emphasize tolerability narratives for short exploratory studies. Any AMPK / mitochondrial modulator theoretically touches energy metabolism systemically; legitimate use contexts (if any) would be clinician- and trial-supervised. Unregulated products: unknown identity, purity, and contaminants. Not medical advice.
What is ATX-304's regulatory status?
- U.S.: Not FDA-approved for obesity, diabetes, or other indications as of November 10, 2026.
- EU / other: No broad marketing authorisation identified in draft checks.
- Sport: AMPK activators as a class appear on WADA’s Prohibited List (metabolic modulators). Whether a specific investigational code is named in a given year’s list can change — athletes should check current WADA list / GlobalDRO, not forums.
- Gray market: “Research use only” sales are not approved medicines.
Why doesn't this page include a dosage chart?
No U.S. approved labeled dose for public prescribing; trial regimens are not consumer protocols; “ATX-304 dosage” / “O-304 dosage” queries often seek gray-market instructions. Literacy refusal.
Related lab literacy
Peptide reconstitution pages are not applicable to an oral small molecule. Linked for cluster comparison only: What are peptides?
Related compounds and comparisons
- Semaglutide / Tirzepatide — approved peptide incretin drugs (different class).
- Tesofensine — another non-peptide metabolic literacy profile (monoamine reuptake).
- Cardarine (GW501516) — PPARδ agonist research compound (also not a peptide; distinct toxicity/WADA story).
- SLU-PP-915 — pan-ERR agonist research tool (exercise-mimetic adjacency; not a peptide).
Frequently asked questions
Is ATX-304 a peptide?
No. It is an investigational oral small-molecule AMPK activator (formerly O-304). Weight-loss search adjacency causes category confusion with peptide drugs.
Is ATX-304 the same as O-304?
Yes in identity terms: ATX-304 is the later sponsor designation for the compound previously published and developed as O-304 / O304. Always cross-check the molecular identity in primary sources.
Is ATX-304 FDA approved?
No, not in the United States as of November 10, 2026.
How does it differ from semaglutide or tirzepatide?
Those are peptide incretin-receptor agonists with approved U.S. labels for specific indications. ATX-304 targets AMPK / mitochondrial energy narratives as a small molecule and is investigational.
Is it an “exercise mimetic”?
Sponsor and preclinical narratives compare metabolic effects to aspects of aerobic training (energy expenditure, substrate use). That framing is research language — not a license to self-experiment or a sports recommendation.
Why is this on a peptide tutorials site?
Metabolic/weight-loss search demand clusters AMPK candidates with peptide drugs. We publish a literacy profile with an explicit chemistry-class correction.
Why no dosage information?
YMYL policy and lack of U.S. approved labeling for consumer dosing. We will not invent a chart from trial abstracts.
Are research-chemical ATX-304 products legitimate medicine?
Unregulated products are not FDA-approved medicines. Identity and purity are uncertain.
ATX-304 (O-304) is not a peptide and is not FDA-approved. Educational only. Disclaimer.
Sources
The sources below were checked against PubMed, DailyMed, or the official agency page on November 10, 2026 (America/Phoenix). Links go to the publisher, PubMed, or the agency record.
- Primary — animal Holm E, Vermeulen I, Parween S, et al. AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching. JCI Insight. 2025. doi:10.1172/jci.insight.179990. PMID: 40197369. Preclinical mouse model of fatty liver disease, not a human trial.
- Anti-doping World Anti-Doping Agency. The World Anti-Doping Code International Standard Prohibited List 2026. Accessed November 10, 2026. Confirm the current list and GlobalDRO before relying on sport status. The 2026 list discusses AMPK activators as a class (examples include BAM15, AICAR, and MOTS-c). ATX-304 was not listed by that name on the page we checked; athletes should still check GlobalDRO.
- Written by
- Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
- Published · Updated
- Oct 6, 2026 · Oct 6, 2026 · Regulatory and sport-status wording checked November 10, 2026 against current FDA labels and the 2026 WADA Prohibited List · How we source & update
Educational disclaimer: Educational only. ATX-304 (O-304) is not a peptide and is not FDA-approved. No dosing or buy links. We don’t sell peptides. Read our full disclaimers.